A5088310205- Heart Failure Treatment and Management
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Transplantation: Methods and Outcomes
- Cardiovascular Function and Risk Factors
- Cardiac Arrest and Resuscitation
- Renal Transplantation Outcomes and Treatments
- Cardiac pacing and defibrillation studies
- Cardiovascular Issues in Pregnancy
- Organ Transplantation Techniques and Outcomes
- Cardiac Valve Diseases and Treatments
- Pulmonary Hypertension Research and Treatments
- Potassium and Related Disorders
- Viral Infections and Immunology Research
- Cardiovascular and exercise physiology
- Diabetes Treatment and Management
- Cardiac Arrhythmias and Treatments
- Congenital Heart Disease Studies
- Electrolyte and hormonal disorders
- Hemodynamic Monitoring and Therapy
- Liver Disease and Transplantation
- Blood Pressure and Hypertension Studies
- Cardiac electrophysiology and arrhythmias
- Hepatitis C virus research
- Health Systems, Economic Evaluations, Quality of Life
Brigham and Women's Hospital
2015-2024
Harvard University
2015-2024
Twitter (United States)
2024
Maine Medical Center
2023
Mayo Clinic in Arizona
2019
Clinical Research Institute
2013-2019
Massachusetts General Hospital
2016-2018
House of Representatives
2017
University of Pittsburgh Medical Center
2016
National Heart Lung and Blood Institute
2013-2016
Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there few prospective data to guide their use.
<h3>Importance</h3>Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function thus exercise capacity with preserved ejection fraction (HFPEF).<h3>Objective</h3>To determine the effect of inhibitor sildenafil compared placebo on clinical status HFPEF.<h3>Design</h3>Multicenter, double-blind, placebo-controlled, parallel-group, randomized trial 216 stable outpatients HF, ≥50%, elevated N-terminal brain-type natriuretic...
Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little known about efficacy and safety ultrafiltration in failure complicated by persistent congestion worsened renal function.We randomly assigned a total 188 failure, function, stepped pharmacologic (94 patients) or patients). The primary end point was bivariate change from baseline serum creatinine level body weight, as assessed 96 hours after random...
Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has beneficial hemodynamic effects in patients with decompensated congestive heart failure. We investigated the clinical use nesiritide such patients.
◼ angioedema angiotensin-converting enzyme inhibitors angiotensin receptor blockers
<h3>Importance</h3> Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies patients failure, irrespective type 2 diabetes status. <h3>Objective</h3> To test whether therapy a GLP-1 agonist improves stability following hospitalization for acute failure. <h3>Design, Setting, and Participants</h3> Phase...
Abstract —Pulmonary vascular resistance is frequently elevated in patients with chronic left ventricular failure as a result of dysregulation smooth muscle tone and structural remodeling. The former reversible over period minutes to days by pharmacological vasodilators, whereas the latter relatively fixed may resolve only slowly, months years. These abnormalities are due, at least part, pulmonary endothelial dysfunction that results impaired nitric oxide availability increased endothelin...
Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) sodium-glucose co-transporter-2 inhibitors. However, few of these had HF, and those that did were not well-characterized. Thus, the effects inhibitors established HF ejection fraction, including without mellitus, remain unknown.DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms Functional Status Patients Reduced Ejection Fraction) was an investigator-initiated,...
Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat virus (HCV) infection has raised the possibility substantially increasing donor organ pool by enabling transplantation hearts HCV-infected into recipients who do have HCV infection.
<h3>Importance</h3> Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation AHF. <h3>Objective</h3> To assess effect high-dose spironolactone usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared alone. <h3>Design, Setting, Participants</h3> This...
Data showing the efficacy and safety of transplantation hearts obtained from donors after circulatory death as compared with brain are limited. Download a PDF Research Summary. We conducted randomized, noninferiority trial in which adult candidates for heart were assigned 3:1 ratio to receive donor or if that was available first (circulatory-death group) only had been preserved use traditional cold storage (brain-death group). The primary end point risk-adjusted survival at 6 months...
<h3>Importance</h3> The use of sacubitril/valsartan is not endorsed by practice guidelines for in patients with New York Heart Association class IV heart failure a reduced ejection fraction because limited clinical experience this population. <h3>Objective</h3> To compare treatment valsartan advanced and recent symptoms. <h3>Design, Setting, Participants</h3> A double-blind randomized trial was conducted; total 335 were included. began on March 2, 2017, stopped early 23, 2020, owing to...